Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 3b clinical study titled A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain. The study aims to assess the safety and effectiveness of elagolix, in combination with combined oral contraceptives, in treating dysmenorrhea in women with endometriosis. This condition affects a significant portion of women of childbearing age, impacting their daily lives and mental health.
The study is testing the drug elagolix, an approved treatment for endometriosis-related pain, alongside combined oral contraceptives. The goal is to determine how well this combination works compared to a placebo.
This interventional study is randomized and uses a parallel assignment model. It employs a quadruple masking approach, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment.
The study began on April 2, 2020, with the primary completion date yet to be announced. The last update was submitted on September 3, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
AbbVie’s ongoing study could influence its stock performance positively if results show significant efficacy and safety, as it may lead to expanded use of elagolix. This could also impact investor sentiment, especially if competitors in the endometriosis treatment market are not conducting similar studies.
The study is currently recruiting, with further details available on the ClinicalTrials portal.